TPTX Turning Point Therapeutics, Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyís lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naÔve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointís kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

$75.21  -0.07 (-0.09%)
As of 06/28/2022 14:46:34 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/17/2019
Outstanding shares:  49,666,288
Average volume:  4,097,061
Market cap:   $3,733,414,869
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJXBP30
Valuation   (See tab for details)
PE ratio:   -13.57
PB ratio:   4.19
PS ratio:   614.23
Return on equity:   -30.91%
Net income %:   -4,532.46%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy